Duvelisib

Research use only, not for human use.

A potent, selective PI3Kδ/γ inhibitor with Ki of 23 pM/243 pM, IC50 of 1 nM/50 nM.

A potent, selective PI3Kδ/γ inhibitor with Ki of 23 pM/243 pM, IC50 of 1 nM/50 nM; displays high selectivity for PI3K δ/γ than other protein kinases; exerts profound effects on adaptive and innate immunity by inhibiting B and T cell proliferation, blocking neutrophil migration, and inhibiting basophil activation; exhibits potent activity in collagen-induced arthritis, ovalbumin-induced asthma, and systemic lupus erythematosus rodent models.Blood Cancer Phase 3 Clinical.

PI3Kδ and PI3Kγ inhibition with Duvelisib (IPI-145) has anti-proliferative activity in primary AML cells by inhibiting the activity of AKT and MAPK. Pre-treatment of AML cells with Duvelisib inhibits both adhesion and migration of AML blasts to bone marrow stromal cells.

——

IPI-145 | INK-1197

PI3K/Akt/mTOR signaling

PI3K

PI3Kα|PI3Kβ|PI3Kγ|PI3Kδ

Cancer

Blood cancer

1201438-56-3

416.863

C22H17ClN6O

>98% (HPLC)

DMSO: ≥ 41 mg/mL

O=C1N(C2=CC=CC=C2)C([C@@H](NC3=C4N=CNC4=NC=N3)C)=CC5=C1C(Cl)=CC=C5

1(2H)-Isoquinolinone, 8-chloro-2-phenyl-3-[(1S)-1-(9H-purin-6-ylamino)ethyl]-

(-20℃)

With Ice Pack

≥ 2 years